Spironolactone

Spironolactone has been studied in 60 papers since 1999: 8 trials and 23 observational studies in people, 4 in animals, 23 reviews; 35 in the past year. It is an approved medicine. The newest paper, Nov 16, 2026: “Cardioprotective Interventions During Anthracycline-Based Chemotherapy: A Systematic Review and Network Meta-Analysis”.

InterventionApproved 1960

60 papers study it21 more mention it40 findingsUpdated

PubChemChEBIMeSH

20 new papers in 30 daysSee all 80 papers on spironolactone

At a glance

Spironolactone extends lifespan in klotho-hypomorphic mice in one group's study; a human trial reports lower mortality in older women with HFpEF. Reviews describe independently replicated ejection-fraction improvements in chemotherapy-treated breast cancer patients; another human trial shows no clear frailty benefit in HFpEF. Trials report hyperkalemia; some papers declare company ties, and some trials are Pfizer-sponsored.

40 findings in 28 papers from 1993 to 2026, 8 of them since May 2026

Independent labs found the same change in people. 22 independent labs in 11 countries; 127 trials, 3 about aging, 34 with no results posted.

“Randomization to active therapies increased the percentage of TIR across trials, by 3% (95%CI −1 to 7%) with spironolactone”
Time in blood pressure range and cardiovascular outcomes in HFmrEF/HFpEF: a pooled participant-level analysis of four large-scale trialsESC Congress 2026 abstract2026doi:10.1093/eurheartj/ehag785.1095

None of its findings points the other way.

Humans: replicated by independent labs. Cells and mice: a single group. Worms or flies: nothing yet.
  • 22 independent labs in 11 countries
  • 127 trials, 3 about aging, 34 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 6 of 36 findings with company ties
  • 2 of 127 trials sponsored by its developers
  • Human trial8
  • Humans22
  • Animals4

7 studies gave spironolactone to people and measured what changed.

What changedDesignPeopleSource

up: Increases time in target systolic blood pressure range3% (95% CI −1 to 7%)

Review of trialsfirst year18,823 people pooledBothmean age 72±9 yearsOlder adults; Heart failure with LVEF ≥45%; target systolic blood pressure 110–<130 mmHgESC Congress 2026 abstract, Oct 26, 2026

up: Increases serum potassium

up: Increases discontinuation due to hyperkalemia

Randomized trial72 weeks168 peopleelderlyOlder adults; on irbesartan background therapyThe American journal of the medical sciences, May 20, 2026

no change: Has no effect on health status

Randomized trial9 months527 peopleBothmedian 73 yearsOlder adults; Patient cohortsRevista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, Mar 21, 2026

down: Decreases PICP

Randomized trial9 months488 peopleIn patients at risk of heart failureMedComm, Feb 17, 2026

down: Lowers the risk of mortality10.0 vs. 7.3%, HR 0.68, 95% CI 0.48–0.96

Treated cohortabout 3.3 years1,619 people898 (55.5%) were women, and 721 (44.5%) were men≥70 yearsElderly heart failure patients with preserved ejection fractionFrontiers in cardiovascular medicine, Oct 4, 2021

What did studies of spironolactone find?

29

Studies of spironolactone measured 29 outcomes, among them left ventricular ejection fraction, home systolic blood pressure and systolic blood pressure.

Left ventricular ejection fraction

upin humans2

2 studies
  1. Spironolactone increases left ventricular ejection fraction in humans (receiving anthracycline-based chemotherapy; compared with Control) (MD 12.08 percentage points, 95% CrI 3.57–20.65).

    Reviewreceiving anthracycline-based chemotherapy; compared with Controlheart

  2. Spironolactone increases left ventricular ejection fraction in humans (breast cancer patients undergoing chemotherapy; compared with placebo) (MD 12.80; 95% CrI 5.99 to 19.60).

    Reviewbreast cancer patients undergoing chemotherapy; compared with placeboheart

Home systolic blood pressure

downin humans1

1 study
  1. Spironolactone decreases home systolic blood pressure in humans (Resistant hypertension; versus placebo in PATHWAY-2) (8.70 mmHg versus placebo; 4.48 mmHg versus bisoprolol).

    ReviewResistant hypertension; versus placebo in PATHWAY-2

Systolic blood pressure

downin humans1

1 study
  1. Spironolactone decreases systolic blood pressure in humans (resistant hypertension) (-20.1 mmHg (95% CI -31.2 to -9.1)).

    Reviewresistant hypertensionn = 230

Apnea-hypopnea index

downin humans1

1 study
  1. Spironolactone decreases apnea-hypopnea index in humans (obstructive sleep apnea; compared with placebo) (MD −22.68 events/h; 95% CI, −25.42 to −19.93).

    Reviewobstructive sleep apnea; compared with placebo

Time in target systolic blood pressure range

upin humans1

1 study
  1. Spironolactone increases time in target systolic blood pressure range in humans (Heart failure with LVEF ≥45%; target systolic blood pressure 110–<130 mmHg) (3% (95% CI −1 to 7%)).

    Human trialHeart failure with LVEF ≥45%; target systolic blood pressure 110–<130 mmHgfirst year

More on Time in target systolic blood pressure range

Auditory thresholds

downin mice1

1 study
  1. Spironolactone impairs auditory thresholds in mice (attenuated benefits of Dkk3 knockdown or aldosterone supplementation).

    Animalsattenuated benefits of Dkk3 knockdown or aldosterone supplementation

Discontinuation due to hyperkalemia

upin humans1

1 study
  1. Spironolactone increases discontinuation due to hyperkalemia in humans (on irbesartan background therapy).

    Human trialon irbesartan background therapy20 mg/d72 weeks

Serum potassium

upin humans1

1 study
  1. Spironolactone increases serum potassium in humans (on irbesartan background therapy).

    Human trialon irbesartan background therapy20 mg/d72 weeks

More on Serum potassium

Systolic blood pressure

downin humans1

1 study
  1. Spironolactone decreases systolic blood pressure in humans (compared with placebo in resistant hypertension) (-13.3 mm Hg (95% CI, -17.89 to -8.72)).

    Reviewcompared with placebo in resistant hypertension25-50 mg/dn = 3,485

More on Systolic blood pressure

Health status

no changein humans1

1 study
  1. Spironolactone showed no clear effect on health status in humans.

    Human trial9 months

PICP

downin humans1

1 study
  1. Spironolactone decreases PICP in patients at risk of heart failure.

    Human trialin patients at risk of heart failure

More on PICP

Frailty

no changein humans1

1 study
  1. Spironolactone showed no clear effect on frailty in patients with heart failure with preserved ejection fraction (aOR 0.85, 95% CI 0.67 to 1.09).

    Human trialin patients with heart failure with preserved ejection fraction1-yearn = 1,767

Outcomes by frailty class (no interaction between frailty and treatment effect)

no changein humans1

1 study
  1. Spironolactone showed no clear effect on outcomes by frailty class (no interaction between frailty and treatment effect) in HFpEF patients across frailty classes.

    Human trialin HFpEF patients across frailty classesn = 1,767

Arterial stiffness

no changein humans1

1 study
  1. Spironolactone showed no clear effect on arterial stiffness in humans (older adults with stable compensated HFpEF).

    Human trialolder adults with stable compensated HFpEF25 mg/d9 months

More on Arterial stiffness

Blood pressure

downin humans1

1 study
  1. Spironolactone decreases blood pressure in humans (older adults with stable compensated HFpEF).

    Human trialolder adults with stable compensated HFpEF25 mg/d9 months

More on Blood pressure

All 29

What is spironolactone linked with?

8

Studies link spironolactone with 8 measures, among them mortality, composite adverse cardiovascular events and annual rate of estimated glomerular filtration rate decline.

Mortality

downin humans2HR 0.68

2 studies
  1. Spironolactone lowers the risk of mortality in women (10.0 vs. 7.3%, HR 0.68, 95% CI 0.48–0.96).

    Human trialin womenabout 3.3 yearsn = 898

  2. Spironolactone lowers the risk of mortality in humans (elderly HFpEF) (HR 0.68, 95% CI 0.48-0.96).

    Human trialelderly HFpEFfemales

  3. Spironolactone lowers the risk of mortality in humans (HR 0.68, 95% CI 0.48-0.96).

    Human trialelderly patients with HFpEF (TOPCAT); no significant sex-treatment interaction (p interaction=0.190)femalesn = 898

Composite adverse cardiovascular events

downin humans1HR 0.7

1 study
  1. Spironolactone lowers the risk of composite adverse cardiovascular events in humans (heart failure) (HR: 0.70).

    Reviewheart failure4–44 months

Annual rate of estimated glomerular filtration rate decline

upin humans1

1 study
  1. Spironolactone is associated with annual rate of estimated glomerular filtration rate decline in humans (Type 2 diabetes and persistent proteinuria despite SGLT2i therapy) (Median annual eGFR change from -2.2 to 1.3 mL/min/1.73 m2/year; p=0.001).

    HumansType 2 diabetes and persistent proteinuria despite SGLT2i therapyMonths 3–12 after spironolactone initiationn = 29

Urinary protein-to-creatinine ratio

downin humans1

1 study
  1. Spironolactone is associated with urinary protein-to-creatinine ratio in humans (Type 2 diabetes and persistent proteinuria despite more than six months of SGLT2i therapy) (Median UPCR decreased from 0.70 to 0.15 g/g creatinine).

    HumansType 2 diabetes and persistent proteinuria despite more than six months of SGLT2i therapy12 monthsn = 29

More on Urinary protein-to-creatinine ratio

Adverse effects

upin humans1

1 study
  1. Spironolactone is linked with a higher risk of adverse effects in humans (doses >50 mg vs <=50 mg in primary aldosteronism) (39.1% vs 29.3%).

    Humansdoses >50 mg vs <=50 mg in primary aldosteronismn = 394

Fall risk

upin humans1OR 4.1

1 study
  1. Spironolactone is linked with a higher risk of fall risk in humans (older adults) (OR = 4.10, p = 0.001).

    Humansolder adultsn = 200

Osteoporosis

downin humans1OR 0.385

1 study
  1. Spironolactone is linked with a lower risk of osteoporosis in middle-aged and elderly hypertensive patients (post-match: OR 0.385, 95% CI, 0.259-0.571).

    Humansin middle-aged and elderly hypertensive patients

More on Osteoporosis

Community-acquired hyperkalemia

upin humans1OR 2.53

1 study
  1. Spironolactone is associated with community-acquired hyperkalemia in humans (OR 2.530).

    Humans

More on Community-acquired hyperkalemia

Has spironolactone been tested in people?

3 of 127 about aging

Yes: 8 trials and 23 observational studies in people have been published, and 127 trials are registered.

Approved

  • FDA Aldactone

    Jan 21, 1960Edema, Heart Failure, Hypertension, Nephrotic Syndrome, heart failure and reduced ejection fraction, cirrhosis of the liver, high blood pressure, primary hyperaldosteronism, hepatic cirrhosis

  • FDA Carospir

    Aug 4, 2017Edema, Heart Failure, Hypertension, high blood pressure, heart failure and reduced ejection fraction, Cirrhosis

  • EMA Qaialdo

    May 26, 2023Edema, Heart Failure, Liver Cirrhosis, Ascites, Nephrotic Syndrome, Hyperaldosteronism, Essential Hypertension, primary aldosteronism, congestive cardiac failure, malignant ascites, hepatic cirrhosis

Repurposing

40 of 72

Every condition in trials

  • Hypertension Resistant to Conventional Therapy

    Phase 4Completed3 trials

  • Autosomal dominant polycystic kidney

    Phase 3Results posted1 trial

  • Aml

    Phase 1/2Completed1 trial

  • Leukemia myeloid acute

    Phase 1/2Status unknown1 trial

  • Alcohol drinking

    Phase 1Recruiting1 trial

  • Bioequivalence study

    Phase 1Completed1 trial

Stopped

  • NCT03597035TerminatedHyperkalemia

    The study could not enroll patients owing to the inclusion exclusion criteria

  • NCT03777319TerminatedDuchenne muscular dystrophy

    Inability to recruit participants.

  • NCT01843309Terminated

    Not possible to complete the sample within the estimated time by the use of new antifungals

Who is developing spironolactone?

3 companies: CMP Development, AstraZeneca and Sarfez Pharmaceuticals.

Companies
  • CMP DevelopmentPhase 4edema due to heart failure or cirrhosis
  • AstraZenecaPhase 4hyperkalaemia, heart failure with reduced ejection fraction
  • Sarfez PharmaceuticalsPhase 3bioequivalence study in healthy subjects, pk/pd

Trial sponsors

Funding

1 grant since 2025

American Heart Association

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 2Jan 2026: 6Feb 2026: 3Mar 2026: 6Apr 2026: 0May 2026: 2Jun 2026: 0Jul 2026: 1Aug 2026: 5Sep 2026: 1Oct 2026: 8Nov 2026: 1145 papers in 12 months

See all 80 papers on spironolactone